Sativex (nabiximols) for the treatment of Agitation & Aggression in Alzheimer’s dementia in UK nursing homes: a randomised, double-blind, placebo-controlled feasibility trial
Despite significant COVID-19 pandemic related challenges, administering nabiximols through oral mucosa to advanced ad patients with agitation demonstrated feasibility and safety. These findings support a larger confirmatory efficacy trial to evaluate the potential therapeutic efficacy of nabiximols for agitation in ad.
Authors
- Sagnik Bhattacharyya (ORCID: https://orcid.org/0000-0002-8688-8025)
- Ta‐Wei Guu (ORCID: https://orcid.org/0000-0002-2621-0781)
- Christopher P. Albertyn (ORCID: https://orcid.org/0000-0002-4682-6890)
- Ben Carter (ORCID: https://orcid.org/0000-0003-0318-8865)
- Latha Velayudhan (ORCID: https://orcid.org/0000-0002-7712-930X)
- Dag Aarsland (ORCID: https://orcid.org/0000-0001-6314-216X)
- Allan H. Young (ORCID: https://orcid.org/0000-0003-2291-6952)
- Simrat Kaur (ORCID: https://orcid.org/0000-0001-7180-6392)
- Petrina Chu (ORCID: https://orcid.org/0000-0002-5743-5262)
- Pooja Kandangwa
- Byron Creese (ORCID: https://orcid.org/0000-0001-6490-6037)
- Hassan Jafari (ORCID: https://orcid.org/0000-0002-4541-6419)
Institutions
- King's College London (GB)
- China Medical University (TW)
- Stavanger University Hospital (NO)
- China Medical University Beigang Hospital (TW)
- Psychiatry Research Trust (GB)
- Brunel University of London (GB)
- China Medical University (CN)
Publication Details
- Journal
- Age and Ageing
- Published
- 2025-05-21
- DOI
- https://doi.org/10.1093/ageing/afaf149
- Citations
- 4
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 5.58